Vera Therapeutics’ once-weekly injection Trutakna has received expedited FDA approval for treating adult primary immunoglobulin A nephropathy (IgAN). This first-in-class therapy targets both B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), addressing the disease’s underlying autoimmune mechanisms more comprehensively than existing options.
The treatment specifically benefits IgAN patients at risk of kidney function decline. Unlike traditional off-label corticosteroid use, Trutakna directly inhibits autoantibody production through its dual-target mechanism. Clinical trials showed significant 42% reduction in urine protein levels compared to placebo, marking clinically meaningful progress in kidney preservation.
Vera’s drug stands out from previous IgAN therapies like Merck KGaA’s Tarpeyo and other monoclonal antibodies by blocking two disease-driving pathways simultaneously. While Otsuka’s Voyxact (APRIL-targeted) holds early market advantage, Vertex’s upcoming dual-target drug povetacicept introduces potential competition. Trutakna’s $425,000 annual price reflects its broader therapeutic approach.
Ongoing Phase 3 research aims to confirm long-term kidney function improvements through estimated glomerular filtration rate (eGFR) measurements. Vera Therapeutics maintains this accelerated approval pending final trial results expected this quarter. The company’s dual-inhibition strategy opens potential applications beyond nephrology, targeting 11 autoimmune conditions across a $10 billion market opportunity.
